194 related articles for article (PubMed ID: 24173087)
1. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms.
Fantasia F; Di Capua EN; Cenfra N; Pessina G; Mecarocci S; Rago A; Cotroneo E; Busanello A; Equitani F; Lo-Coco F; Nervi C; Cimino G
Ann Hematol; 2014 Apr; 93(4):609-16. PubMed ID: 24173087
[TBL] [Abstract][Full Text] [Related]
2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract][Full Text] [Related]
4. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
5. The Combination of
Wu S; Luo P; Rouzi T; Yu Y; Xiong B; Wang Y; Zuo X
Cancer Control; 2023; 30():10732748231163648. PubMed ID: 36895113
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of
Yönal-Hindilerden İ; Şahin E; Hindilerden F; Dağlar-Aday A; Nalçacı M
Turk J Haematol; 2023 Aug; 40(3):174-182. PubMed ID: 37584526
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms.
dos Santos MT; Mitne-Neto M; Miyashiro K; Chauffaille Mde L; Rizzatti EG
J Clin Pathol; 2014 Feb; 67(2):176-8. PubMed ID: 23986553
[TBL] [Abstract][Full Text] [Related]
8. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
9. Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
Zheng CF; Zhao XX; Chen XH; Liu Z; Wang WJ; Luo M; Ren Y; Wang HW
Int J Lab Hematol; 2021 Aug; 43(4):645-650. PubMed ID: 33973741
[TBL] [Abstract][Full Text] [Related]
10. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Baumeister J; Chatain N; Hubrich A; Maié T; Costa IG; Denecke B; Han L; Küstermann C; Sontag S; Seré K; Strathmann K; Zenke M; Schuppert A; Brümmendorf TH; Kranc KR; Koschmieder S; Gezer D
Leukemia; 2020 Apr; 34(4):1062-1074. PubMed ID: 31728053
[TBL] [Abstract][Full Text] [Related]
12. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
13. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
[TBL] [Abstract][Full Text] [Related]
14. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
15. [The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].
Shen YM; Chao HY; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Nei Ke Za Zhi; 2009 Feb; 48(2):140-3. PubMed ID: 19549471
[TBL] [Abstract][Full Text] [Related]
16. The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.
Şahin E; Yönal-Hindilerden İ; Hindilerden F; Aday A; Nalçacı M
Turk J Med Sci; 2022 Feb; 52(1):150-165. PubMed ID: 34482679
[TBL] [Abstract][Full Text] [Related]
17. [JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation].
Sun CC; Li Y; Tian WJ; Chen YJ; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1022-6. PubMed ID: 25130821
[TBL] [Abstract][Full Text] [Related]
18. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
19. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
[TBL] [Abstract][Full Text] [Related]
20. [Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].
Xu YY; Li HM; Li XJ; Yang L; Hu DM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):541-4. PubMed ID: 19549360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
